BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines PARTRUVIX (pamiparib, PARP Inhibitor) by Year
PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY20–FY23) ($M)
BeOne Medicines PARTRUVIX (pamiparib, PARP Inhibitor): $6.70M in FY2023, up 21.8% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-26) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY20–FY23) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 6.70 | +21.8% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 5.50 | +48.6% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 3.70 | – | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines PARTRUVIX (pamiparib, PARP Inhibitor) ($M), annual FY2020–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-partruvix
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.